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OBJECTIVE — To evaluate neural dysfunction in subjects with impaired glucose tolerance (IGT).
RESEARCH DESIGN AND METHODS — For this study, 46 subjects with IGT and 45
healthy volunteers underwent detailed neurological assessment. Cardiovascular autonomic function
wasassessedbystandardcardiovascularreﬂextests,andheartratevariabilitywascharacterizedbythe
triangleindex.SensorynervefunctionwasassessedusingNeurometer(forcurrentperceptionthresh-
old) and Medoc devices. Peak plantar pressure was measured by dynamic pedobarography, and
symptoms were graded using the neuropathy total symptom score.
RESULTS — SubjectswithIGThadsigniﬁcantlygreaterabnormalitiesdetectedbyfourofﬁve
cardiovascular reﬂex tests and greater heart rate variability characterized by the triangle index.
They had a higher frequency of both hyperesthesia and hypoesthesia as detected by current
perception threshold testing at 5 Hz, as well as increased heat detection thresholds.
CONCLUSIONS — This study provides evidence that subclinical neural dysfunction is
present in subjects with IGT and can be detected noninvasively. Cardiovascular autonomic
neuropathy may contribute to increased cardiovascular risk in IGT subjects.
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S
everal prospective studies have docu-
mented a positive association be-
tween A1C values and speciﬁc
microvascular complications, including
neuropathy (1). The relationship, however,
between impaired glucose tolerance (IGT)
and neuropathy is less clear. There are only
limited and conﬂicting data supporting in-
creases in neuropathy with IGT (2,3). The
aimofourstudywasacomprehensiveeval-
uation of neural dysfunction in IGT
subjects.
RESEARCH DESIGN AND
METHODS— IGT was diagnosed
basedona75-goralglucosetolerancetest
according to World Health Organization
criteria (fasting blood glucose 6.0
mmol/l and 120-min value 7.8–11.0
mmol/l). Subjects with isolated IGT from
our outpatient clinic (n  46) and age-
and sex-matched healthy volunteers with
normal glucose tolerance (n  45) were
assessed (IGT vs. healthy volunteers:
male/female, 21/25 vs. 18/27, P  NS;
mean  SD age, 53.0  11.1 vs. 55.8 
11.4 years, P  NS; fasting plasma glu-
cose, 5.40  0.57 vs. 4.70  0.50
mmol/l, P  0.0001; 120-min plasma
glucose, 8.61  1.01 vs. 4.90  0.45
mmol/l, P  0.0001; A1C, 5.97  0.38
vs. 4.99  0.45%, P  0.0001 [further
data available in online appendix Table
A1 at http://dx.doi.org/10.2337/dc08-
1406]).
The frequency and intensity of neu-
ropathy symptoms were evaluated by the
Neuropathy Total Symptom Score (4).
Sensory function was assessed by a Neu-
rometer R device (Baltimore, Maryland),
Medoc device (Ramat Yishay, Israel), cal-
ibrated128-Hztuningfork,andSemmes-
Weinstein monoﬁlament. Current
perception threshold (CPT) was mea-
sured at the median and peroneal nerves
(digital branches) by the Neurometer at
three different frequencies (2 kHz, 250
Hz, and 5 Hz) assessing large myelinated,
smallmyelinatedandsmallunmyelinated
sensory ﬁber function, respectively (5).
Cold and heat detection thresholds were
assessed by a thermal sensory analyzer
(TSA-II), and vibration perception
threshold(VPT)wasevaluatedbyavibra-
tory sensory analyzer (VSA-3000) on the
Medoc device. Plantar pressure was mea-
sured by dynamic pedobarography.
Cardiovascular autonomic neuropa-
thy was detected by standard cardiovas-
cular reﬂex tests: heart rate responses to
deepbreathingandstanding(30/15ratio)
and the Valsalva maneuver (Valsalva ra-
tio), assessing mainly parasympathetic
function;andbloodpressureresponsesto
standing and sustained handgrip, assess-
ing mainly sympathetic function (6).
Heart rate variability (HRV) was charac-
terized by the triangular index (HRVti).
The HRVti is an estimate of overall HRV,
being a time domain measure of HRV.
HRVti is presented as a conversion of the
R-R intervals into a geometric pattern and
iscalculatedbydividingtheintegralofthe
density distribution by the maximum of
the density distribution. The HRVti is
considered the most reliable single mea-
sure of HRV.
DataareexpressedasmeansSDfor
normally distributed data and as median
(interquartile range) for non-normally
distributed data. The latter variables were
log transformed to adjust for skewness.
For comparison between groups, either

2
tests, two sample t tests, or Mann-
WhitneyUtestswereusedasrequired.To
take into account the difference in BMI,
multiple logistic regression (categorical
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Fromthe
11stDepartmentofMedicine,SemmelweisUniversity,Budapest,Hungary;the
23rdDepartmentof
InternalMedicine,Bajcsy-ZsilinszkyHospital,Budapest,Hungary;the
3DepartmentofEpidemiologyand
PublicHealth,UniversityCollegeLondon,London,UK;and
4RoyalHallamshireHospital,Shefﬁeld,U.K.
Corresponding author: Zsuzsanna Putz, zsuzsannaputz@yahoo.com.
Received 30 July 2008 and accepted 17 September 2008.
Published ahead of print at http://care.diabetesjournals.org on 3 October 2008. DOI: 10.2337/dc08-1406.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
BRIEF REPORT
DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009 181outcomes) and multiple linear regression
(continuous outcomes) were used with
theactualparameterastheoutcomeand
BMI and IGT/control group as predic-
tors. P  0.05 was considered signiﬁ-
cant. All analyses were performed using
SPSS version 14.0. The study protocol
was approved by the local ethics com-
mittee and all subjects gave written in-
formed consent.
RESULTS— Mild-to-moderate symp-
toms of neuropathy were present only in
the IGT group (5 of 41 vs. 0 of 45, P 
0.0056). Both hyperesthesia (7 of 35 vs.
0o f4 4 ,P  0.005), a recognized phe-
nomenon in early neuropathy, and hy-
poesthesia (5 of 37 vs. 0 of 44, P 
0.024), usually seen in later stages of
neuropathy, were detected by Neurom-
eter CPT testing at 5 Hz in more IGT
subjects than healthy volunteers. These
differences, however, lost signiﬁcance
after BMI adjustment.
Compared with healthy volunteers,
heat detection thresholds in IGT sub-
jects were increased in both upper and
lower limbs, whereas a signiﬁcant in-
crease in cold detection threshold was
found in lower limbs only (Table 1).
Signiﬁcant differences were found be-
tween the IGT and control groups in
VPT in both upper and lower limbs, but
there were no signiﬁcant differences be-
tween the two groups with tuning fork
assessment. Peak plantar pressure was
signiﬁcantlyhigherinIGTsubjects,and
signiﬁcant differences were found be-
tween IGT and control subjects in four
of ﬁve classic cardiovascular reﬂex tests
and HRVti. BMI adjustment had only
minor effects on the outcomes except
for a loss of signiﬁcance of cold detec-
tion threshold and VPT.
CONCLUSIONS— There remains
considerable controversy regarding the
relationship between IGT and neuropa-
thy. While observational studies have
shown an increased prevalence of IGT
among subjects with idiopathic neuropa-
thy (7), there are limited data concerning
the prevalence of neuropathy in IGT. The
fewstudiesperformedhaveshownmixed
results (2,3). Part of the explanation for
this may lie in the design of these studies
and the disparate methods used to assess
neuropathy (8).
This study shows that neural impair-
ment in IGT subjects is mainly subclini-
cal, asymptomatic, and characterized by
small-ﬁber neuropathy and mild impair-
ment of cardiovascular autonomic func-
tion. Many population-based studies of
IGT have used methods that predomi-
nantly detect large-ﬁber dysfunction, and
it is therefore not surprising that they
failed to pick up the subtle changes
present in IGT.
Assessment of both CPT at 5 Hz and
heatdetectionthresholdseemstodetect
small-ﬁber neuropathy among IGT sub-
jects. Using the gold-standard punch
skin biopsy, altered morphology and
small-ﬁber neuropathy was previously
identiﬁed in IGT; in that study, IGT
subjects had only small-ﬁber neuropa-
thy, whereas diabetic patients had more
extensive damage, involving both large
and small nerve ﬁbers (9). However,
skin biopsy is clearly not a technique
that can be used as a widespread diag-
nostic tool. Our results indicate that
noninvasive assessment may serve as an
alternative in order to detect neuropa-
thy in IGT. However, simple and popu-
lar noninvasive tests such as the tuning
fork and monoﬁlaments, which assess
mainly large-ﬁber function, did not de-
tect neuropathy in the IGT subjects.
Recently, traditional markers of ma-
crovascular disease, such as hyperten-
sion, obesity, and hyperlipidemia, have
also emerged as risk factors for diabetic
neuropathy (1). These are widely prev-
alent in IGT and may therefore be
equally important in the pathogenesis
ofneuropathyinIGT.Becausewefound
only increased BMI among IGT subjects
andnodifferencesinothercardiovascu-
lar risk factors and because the group
differences were robust for BMI adjust-
ment, it is likely that hyperglycemia per
Table 1—Comparison of noninvasive measurements of neural function between the IGT and the healthy control group
Reference
values
Subjects with IGT
(n  46)
Control subjects
(n  45) P
P adjusted
for BMI
Cold detection threshold (degrees Celsius) 26
Upper limb 30.00 (1.60) 30.20 (0.70) 0.411 0.444
Lower limb 29.00 (3.08) 27.80 (1.60) 0.028 0.059
Heat detection threshold (degrees Celsius) 44
Upper limb 34.35 (3.28) 33.70 (1.20) 0.003 0.002
Lower limb 37.59  4.35 35.54  1.63 0.005 0.007
VPT (Hz) 1.87–4.06
Upper limb 0.62 (0.88) 0.35 (0.26) 0.001 0.005
Lower limb 4.25 (13.28) 2.45 (6.10) 0.007 0.251
Rydel-Seiffer tuning fork 5 8.0 (1.0) 8.0 (1.0) 0.147 0.104
Peak plantar pressure (Pa) 60 52.47  14.15 44.5  7.53 0.002 0.0001
Beat-to-beat variation (bpm) 15 10.00 (4.5) 18.0 (5.0) 0.0001 0.0001
Postural heart rate change (30:15 ratio) 1.04 1.18 (0.11) 1.15 (0.12) 0.385 0.182
Valsalva ratio 1.21 1.25 (0.15) 1.36 (0.34) 0.0001 0.0001
Postural systolic blood pressure changes (mmHg) 10 0 (10) 0 (0) 0.0001 0.0001
Diastolic blood pressure elevation during sustained
handgrip (mmHg)
16 20 (9)* 22 (10) 0.045 0.008
Triangle index 37  15 26.0 (9.3) 40.00 (13.0) 0.0001 0.0001
DataaremeansSDormedian(interquartilerange).Between-groupdifferencesarereportedaccordingtotwo-samplettestsorMann-WhitneyUtestsasindicated.
BMI-adjusted P values determined by multiple linear regression after transformation of the outcomes. *Lower ranks.
Neural impairment in IGT subjects
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the IGT subjects.
Autonomic neuropathy, altered car-
diacvagalresponseinparticular,isacom-
mon early feature of diabetes (10).
Overall, there are limited data on auto-
nomic dysfunction in IGT. However, this
study shows that subjects with IGT have
subtle but detectable changes in auto-
nomic function, and subjects with IGT
have an increased risk of cardiovascular
death (11). Cardiovascular autonomic
neuropathy, although asymptomatic and
mildinnature,mayinpartberesponsible
for this increased risk.
In conclusion, this study has demon-
strated that subclinical small-ﬁber neu-
ropathy and autonomic neuropathy are
commonly present in IGT subjects. Clin-
ical trials are required to study whether
these early losses of nerve function, asso-
ciated with one of the most devastating
complications of diabetes, can be halted
or reversed by glycemic or cardiovascular
risk reduction.
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